Free CME from PeerView


Continuing Nursing Education (CNE) Activities

Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Credits: 0.5 NCPD / ILNA
PVI, PeerView Institute for Medical Education
Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Start

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Media: Enduring Material
Activity Release Date: September 14, 2022
Activity Expiration Date: September 13, 2023
Time to Complete Activity: 30 minutes

Activity Description

Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the care of patients with DLBCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL)
  • Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting
  • Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity
  • Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Nurse Practitioner
Hematology/Oncology
Swedish Cancer Institute
Seattle, Washington

Sonia Glennie, ARNP MSN OCN AGPCNP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

Faculty/Planner
Amy Goodrich, CRNP
Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Amy Goodrich, CRNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc; AstraZeneca; BeiGene; Fresenius Kabi; Genentech, Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from ADC Therapeutics America, Inc., Incyte Corporation, and MorphoSys US Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
0.50 point: Care Continuum, Care of the Pediatric Hematology and Oncology Patient, Cellular Collection, Preparative Regimens, and Infusion, Disease-Related Biology, Early Post-Transplant Management, Foundations of Transplant, Late Post-Transplant Management, Oncologic Emergencies, Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, Palliative Care, Supportive Care, Transplant Process and Infusion, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Media: Enduring Material
Activity Release Date: September 14, 2022
Activity Expiration Date: September 13, 2023
Time to Complete Activity: 30 minutes

Activity Description

Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the care of patients with DLBCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL)
  • Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting
  • Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity
  • Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Nurse Practitioner
Hematology/Oncology
Swedish Cancer Institute
Seattle, Washington

Sonia Glennie, ARNP MSN OCN AGPCNP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

Faculty/Planner
Amy Goodrich, CRNP
Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Amy Goodrich, CRNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc; AstraZeneca; BeiGene; Fresenius Kabi; Genentech, Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from ADC Therapeutics America, Inc., Incyte Corporation, and MorphoSys US Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
0.50 point: Care Continuum, Care of the Pediatric Hematology and Oncology Patient, Cellular Collection, Preparative Regimens, and Infusion, Disease-Related Biology, Early Post-Transplant Management, Foundations of Transplant, Late Post-Transplant Management, Oncologic Emergencies, Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, Palliative Care, Supportive Care, Transplant Process and Infusion, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 14, 2022
Credits: 1.0 CME / NCPD / CPE
AGA Institute
An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Start

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Activity Description and Educational Objectives

In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation.

You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options.

Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction.

Upon completion of this activity, participants should be better able to:

  • Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
  • Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
  • Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.

Patient Advocate
Johannah Ruddy, MEd

Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the AGA Institute are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the AGA Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Activity Description and Educational Objectives

In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation.

You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options.

Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction.

Upon completion of this activity, participants should be better able to:

  • Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
  • Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
  • Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.

Patient Advocate
Johannah Ruddy, MEd

Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the AGA Institute are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the AGA Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 12, 2022
Credits: 1.0 CME / MOC / NCPD
Medical Learning Institute, Inc.
Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Start

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
  • Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
  • Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
  • Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Faculty Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
  • Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
  • Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
  • Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Faculty Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 02, 2022
Credits: 1.0 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Start

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease


Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
  • Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
  • Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo Oncology, Inc.

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.; Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation; Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease


Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
  • Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
  • Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo Oncology, Inc.

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.; Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation; Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 02, 2022
Credits: 0.5 CME / MOC / NCPD / IPCE
PVI, PeerView Institute for Medical Education
Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Start

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Expert commentary is based on data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
  • Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
  • Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.

Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California

Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Expert commentary is based on data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
  • Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
  • Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.

Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California

Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 30, 2022
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Start

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
  • Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
  • Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri

Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.

Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC

Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


 

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
  • Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
  • Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri

Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.

Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC

Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


 

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 26, 2022
Credits: 1.0 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Start

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?


Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
  • Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
  • Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
  • Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
  • Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABP MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?


Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
  • Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
  • Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
  • Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
  • Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABP MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 18, 2022
Credits: 1.0 CME / MOC / NCPD / ILNA
PVI, PeerView Institute for Medical Education
Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Start

Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Media: Enduring Material
Activity Release Date: August 16, 2022
Activity Expiration Date: September 15, 2023
Time to Complete Activity: 60 minutes

Activity Description

Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies.

In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations.

Target Audience

This activity has been designed to meet the educational needs of medical and clinical oncologists, pathologists, molecular pathologists, advanced practice providers, nurses, and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes
  • Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection
  • Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations
  • Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Monopteros Therapeutics; Merus; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; Touch Medical Media; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

Faculty/Planner
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Co-Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

George D. Demetri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Bessor Pharma; Caris Life Sciences; CellCarta; C4 Therapeutics, Inc.; EMD Serono; Erasca, Inc.; G1 Therapeutics; GlaxoSmithKline; ICON plc; Ikena Oncology; ImmuneID, Inc.; Kojin Therapeutics, Inc.; Mirati Therapeutics, Inc.; Rain Therapeutics; Relay Therapeutics; Sanofi; and Synlogic.
Grant/Research Support from Adaptimmune Therapeutics plc; Bayer Corporation; Daiichi Sankyo; GlaxoSmithKline; Janssen; Novartis Pharmaceuticals Corporation; PharmaMar; Pfizer; and Roche/Genentech.
Other Financial or Material Support Board of Directors/Advisory Board Consultant for Blueprint Medicines.

Faculty/Planner
Vivek Subbiah, MD
Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Executive Medical Director
Department of Medical Oncology Research
MD Anderson Cancer Center Network
Houston, Texas

Vivek Subbiah, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo, Inc.; Helsinn Pharmaceuticals; Incyte; Lilly; Loxo Oncology; MedImmune; Novartis Pharmaceuticals Corporation; Pfizer; QED Pharma; Relay Therapeutics; Roche/Genentech; and Signant Health.
Grant/Research Support from AbbVie; Agensys Inc.; Alfasigma USA, Inc.; Altum Pharmaceuticals, Inc.; Amgen Inc.; Bayer Corporation; Berg LLC; Blueprint Medicines; Boston Biomedical, Inc.; Boston Pharmaceuticals; Celgene; D3 Pharma; Dragonfly Therapeutics; Exelixis; FUJIFILM Pharmaceuticals U.S.A., Inc.; GlaxoSmithKline; Helsinn Pharmaceuticals; Idera; Incyte; Inhibrx, Inc.; Lilly; Loxo Oncology; MedImmune; MultiVir, Inc.; NanoCarrier Co., Ltd.; Northwest Biotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; Roche/Genentech; Takeda; Turning Point Therapeutics; and Vegenics.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Media: Enduring Material
Activity Release Date: August 16, 2022
Activity Expiration Date: September 15, 2023
Time to Complete Activity: 60 minutes

Activity Description

Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies.

In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations.

Target Audience

This activity has been designed to meet the educational needs of medical and clinical oncologists, pathologists, molecular pathologists, advanced practice providers, nurses, and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes
  • Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection
  • Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations
  • Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Monopteros Therapeutics; Merus; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; Touch Medical Media; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

Faculty/Planner
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Co-Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

George D. Demetri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Bessor Pharma; Caris Life Sciences; CellCarta; C4 Therapeutics, Inc.; EMD Serono; Erasca, Inc.; G1 Therapeutics; GlaxoSmithKline; ICON plc; Ikena Oncology; ImmuneID, Inc.; Kojin Therapeutics, Inc.; Mirati Therapeutics, Inc.; Rain Therapeutics; Relay Therapeutics; Sanofi; and Synlogic.
Grant/Research Support from Adaptimmune Therapeutics plc; Bayer Corporation; Daiichi Sankyo; GlaxoSmithKline; Janssen; Novartis Pharmaceuticals Corporation; PharmaMar; Pfizer; and Roche/Genentech.
Other Financial or Material Support Board of Directors/Advisory Board Consultant for Blueprint Medicines.

Faculty/Planner
Vivek Subbiah, MD
Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Executive Medical Director
Department of Medical Oncology Research
MD Anderson Cancer Center Network
Houston, Texas

Vivek Subbiah, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo, Inc.; Helsinn Pharmaceuticals; Incyte; Lilly; Loxo Oncology; MedImmune; Novartis Pharmaceuticals Corporation; Pfizer; QED Pharma; Relay Therapeutics; Roche/Genentech; and Signant Health.
Grant/Research Support from AbbVie; Agensys Inc.; Alfasigma USA, Inc.; Altum Pharmaceuticals, Inc.; Amgen Inc.; Bayer Corporation; Berg LLC; Blueprint Medicines; Boston Biomedical, Inc.; Boston Pharmaceuticals; Celgene; D3 Pharma; Dragonfly Therapeutics; Exelixis; FUJIFILM Pharmaceuticals U.S.A., Inc.; GlaxoSmithKline; Helsinn Pharmaceuticals; Idera; Incyte; Inhibrx, Inc.; Lilly; Loxo Oncology; MedImmune; MultiVir, Inc.; NanoCarrier Co., Ltd.; Northwest Biotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; Roche/Genentech; Takeda; Turning Point Therapeutics; and Vegenics.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 16, 2022
Credits: 0.5 NCPD
PVI, PeerView Institute for Medical Education
Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Start

Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Media: Enduring Material
Activity Release Date: August 11, 2022
Activity Expiration Date: August 10, 2023
Time to Complete Activity: 30 minutes

Activity Description

This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners, and nurse navigators.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy
  • Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity
  • Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN
Adult Nurse Practitioner
Department of Hematologic Oncology and Blood Disorders
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Tiffany A. Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
MD Anderson Cancer Center
Department of Lymphoma/Myeloma
Houston, Texas

Tiffany A. Richards, PhD, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Legend Biotech; Sanofi; and Takeda.

Faculty/Planner
Donna D. Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York

Donna D. Catamero, ANP-BC, OCN, CCRC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Legend Biotech.
Grant/Research Support from GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Media: Enduring Material
Activity Release Date: August 11, 2022
Activity Expiration Date: August 10, 2023
Time to Complete Activity: 30 minutes

Activity Description

This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners, and nurse navigators.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy
  • Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity
  • Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN
Adult Nurse Practitioner
Department of Hematologic Oncology and Blood Disorders
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Tiffany A. Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
MD Anderson Cancer Center
Department of Lymphoma/Myeloma
Houston, Texas

Tiffany A. Richards, PhD, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Legend Biotech; Sanofi; and Takeda.

Faculty/Planner
Donna D. Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York

Donna D. Catamero, ANP-BC, OCN, CCRC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Legend Biotech.
Grant/Research Support from GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 11, 2022
Credits: 1.0 CME / MOC / NCPD
Penn State College of Medicine
Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?

Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?

Start

Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?

Activity Description and Educational Objectives

Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice.

Upon completion of this activity, participants should be better able to:

  • Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence
  • Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy
  • Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers

Target Audience

This activity has been designed to meet the educational needs of oncologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with advanced gastroesophageal cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME/MOC credit and 75% or higher to obtain NCPD credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 15, 2022 - July 14, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair & Presenter
Yelena Y. Janjigian, MD
Associate Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Yelena Y. Janjigian, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; EMD Serono, Inc.; Imugene Limited; Lilly; Merck & Co., Inc.; Michael J. Hennessy Associates; Paradigm Medical Communications, LLC; Pfizer; Rgenix Inc.; Seagen Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer Corporation; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Lilly; Merck & Co., Inc.; National Cancer Institute; Rgenix Inc; and U.S. Department of Defense.
Stock Shareholder in Rgenix Inc.

Presenter
Steven Maron, MD, MSc
Assistant Attending
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Steven Maron, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Basilea Pharmaceutica Ltd.; Bicara Therapeutics; Daiichi Sankyo Inc.; Natera, Inc.; and Novartis Pharmaceuticals Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6826-22-T.

Support

This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?

Activity Description and Educational Objectives

Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice.

Upon completion of this activity, participants should be better able to:

  • Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence
  • Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy
  • Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers

Target Audience

This activity has been designed to meet the educational needs of oncologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with advanced gastroesophageal cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME/MOC credit and 75% or higher to obtain NCPD credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 15, 2022 - July 14, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair & Presenter
Yelena Y. Janjigian, MD
Associate Professor and Chief of Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Yelena Y. Janjigian, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; EMD Serono, Inc.; Imugene Limited; Lilly; Merck & Co., Inc.; Michael J. Hennessy Associates; Paradigm Medical Communications, LLC; Pfizer; Rgenix Inc.; Seagen Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer Corporation; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Lilly; Merck & Co., Inc.; National Cancer Institute; Rgenix Inc; and U.S. Department of Defense.
Stock Shareholder in Rgenix Inc.

Presenter
Steven Maron, MD, MSc
Assistant Attending
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Steven Maron, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Basilea Pharmaceutica Ltd.; Bicara Therapeutics; Daiichi Sankyo Inc.; Natera, Inc.; and Novartis Pharmaceuticals Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6826-22-T.

Support

This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

July 15, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Start

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes

Activity Description

The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
  • Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
  • Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Faculty Disclosures

Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Pfizer.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy

Media: Enduring Material
Activity Release Date: July 12, 2022
Activity Expiration Date: July 11, 2023
Time to Complete Activity: 60 minutes

Activity Description

The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncology nurses, advanced practice clinicians, pharmacists, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM)
  • Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM
  • Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Sanofi Genzyme.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-054-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Faculty Disclosures

Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical Company Limited; and TG Therapeutics.
Grant/Research Support from Bristol Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Emory University School of Medicine
Adjunct Faculty Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia

Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Pfizer.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

July 12, 2022
Credits: 0.5 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

Start

Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

Expert commentary is based on data presented at the European Hematology Association and American Society of Clinical Oncology meetings 2022.*
*PeerView is an independent publisher of conference news and medical education programs.

Media: Enduring Material
Activity Release Date: June 30, 2022
Activity Expiration Date: June 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, nurses, advanced practice nurses, NPs, PAs, and other healthcare professionals involved in the care of patients with ALL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs
  • Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations
  • Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children’s Hospital
Salt Lake City, Utah

Luke Maese, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals, Inc.
Speakers Bureau participant with Jazz Pharmaceuticals, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice

Expert commentary is based on data presented at the European Hematology Association and American Society of Clinical Oncology meetings 2022.*
*PeerView is an independent publisher of conference news and medical education programs.

Media: Enduring Material
Activity Release Date: June 30, 2022
Activity Expiration Date: June 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, nurses, advanced practice nurses, NPs, PAs, and other healthcare professionals involved in the care of patients with ALL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs
  • Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations
  • Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Luke Maese, DO
Associate Professor, Pediatrics
University of Utah - Huntsman Cancer Institute
Pediatric Hematology/Oncology
Director, Clinical Trial Research Enterprise
Director, Leukemia/Lymphoma Program
Primary Children’s Hospital
Salt Lake City, Utah

Luke Maese, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals, Inc.
Speakers Bureau participant with Jazz Pharmaceuticals, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 30, 2022
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Start

Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.

Target Audience

This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina

David Alain Wohl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Patient/Planner
Benneth Chukwu

Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Taylor Chandler Walker, BC-TCT

Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Omar Martinez, JD, MPH, MS

Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities

Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women.

Target Audience

This activity has been designed to meet the educational needs of HIV specialty care providers, primary care providers, and general practitioners (MD/DO, NP, PA), as well as other workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers), involved in the care of people at risk for being exposed HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women
  • Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
David Alain Wohl, MD
Professor of Medicine, Division of Infectious Diseases
Site Leader, Global Clinical Trials Unit
The University of North Carolina
Chapel Hill, North Carolina

David Alain Wohl, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Patient/Planner
Benneth Chukwu

Benneth Chukwu has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Taylor Chandler Walker, BC-TCT

Taylor Chandler Walker, BC-TCT, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Omar Martinez, JD, MPH, MS

Omar Martinez, JD, MPH, MS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-027-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 21, 2022
Credits: 0.5 CME / MOC / CC / NCPD
PVI, PeerView Institute for Medical Education
The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management

The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management

Start

The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management

Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes

Activity Description

Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course.

In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, rheumatologists, radiologists, pathologists, nurse practitioners, and other clinicians involved in the care of patients with systemic sclerosis-related interstitial lung disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing
  • Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team
  • Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lisa H. Lancaster, MD
Professor of Medicine
Director, Interstitial Lung Disease Program
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Lisa H. Lancaster, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Devpro Biopharma LLC; Pieris Pharmaceuticals, Inc.; and Pliant Therapeutics, Inc.
Grant/Research Support from Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; F. Hoffmann-La Roche Ltd.; FibroGen, Inc.; Galapagos NV; Galecto, Inc; Novartis Pharmaceuticals Corporation; and Pliant Therapeutics, Inc.
Speakers Bureau participant with Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; and Veracyte, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

ABPath The activity titled "The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management" has been registered to offer 0.5 Lifelong Learning credit in the American Board of Pathology's (ABPath) Continuing Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management

Media: Enduring Material
Activity Release Date: June 21, 2022
Activity Expiration Date: June 20, 2023
Time to Complete Activity: 30 minutes

Activity Description

Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course.

In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, rheumatologists, radiologists, pathologists, nurse practitioners, and other clinicians involved in the care of patients with systemic sclerosis-related interstitial lung disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing
  • Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team
  • Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lisa H. Lancaster, MD
Professor of Medicine
Director, Interstitial Lung Disease Program
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Lisa H. Lancaster, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Devpro Biopharma LLC; Pieris Pharmaceuticals, Inc.; and Pliant Therapeutics, Inc.
Grant/Research Support from Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; F. Hoffmann-La Roche Ltd.; FibroGen, Inc.; Galapagos NV; Galecto, Inc; Novartis Pharmaceuticals Corporation; and Pliant Therapeutics, Inc.
Speakers Bureau participant with Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; and Veracyte, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

ABPath The activity titled "The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management" has been registered to offer 0.5 Lifelong Learning credit in the American Board of Pathology's (ABPath) Continuing Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and no contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 21, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

Start

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA.

The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice.

Target Audience

This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
  • Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
  • Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
  • Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.

Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California

Lawrence Eichenfield, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd; Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.; Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics; Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences, Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.

Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community (PRIME-LC)
Santa Ana, California

Charles Vega, MD, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson Services, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Pfizer.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know

Media: Enduring Material
Activity Release Date: June 17, 2022
Activity Expiration Date: June 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA.

The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice.

Target Audience

This activity has been designed to meet the educational needs of nurses, nurse practitioners, physician assistants, and primary care providers involved in the care and treatment of patients with AD and AA.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities.
  • Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets.
  • Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile.
  • Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.

Faculty/Planner
Lawrence Eichenfield, MD
Distinguished Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California
Rady Children’s Hospital
San Diego, California

Lawrence Eichenfield, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, LLC; Arcutis Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals Pte Ltd; Dermata Therapeutics, Inc.; Dermavant Sciences, Inc.; Incyte; LEO Pharma Inc.; Lilly; Ortho Dermatologics; Otsuka America Pharmaceutical, Inc.; Pfizer; Reistone Biopharma; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Arcutis Biotherapeutics; Dermavant Sciences, Inc.; Ortho Dermatologics; and Pfizer.
Speakers Bureau participant with Almirall, LLC; Pfizer; and Sanofi/Regeneron Pharmaceuticals Inc.
Stock Shareholder in Dermata Therapeutics, Inc.; Forte Biosciences, Inc.; and Verrica Pharmaceuticals.
Other Financial or Material Support as an executive role (Board of Directors) for Forte Biosciences, Inc. and Verrica Pharmaceuticals.

Faculty/Planner
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Director
UC Irvine Program in Medical Education for the Latino Community (PRIME-LC)
Santa Ana, California

Charles Vega, MD, FAAFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Johnson & Johnson Services, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Pfizer.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-023-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 17, 2022
Jason Westin, MD, MS, FACP
Credits: 1.5 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice

Start

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice

Media: Enduring Material
Activity Release Date: June 5, 2022
Activity Expiration Date: July 4, 2023
Time to Complete Activity: 90 minutes

Activity Description

Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic.

Check out PeerView’s “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, advanced practice clinicians (including oncology NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with hematologic cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies
  • Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support
  • Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jason Westin, MD, MS, FACP
Associate Professor
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jason Westin, MD, MS, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ADC Therapeutics SA; AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; Merck & Co., Inc.; Monte Rosa Therapeutics, Inc.; MorphoSys AG; Novartis Pharmaceuticals Corporation; and Umoja Biopharma.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; MorphoSys AG; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Shannon L. Maude, MD, PhD
Cancer Immunotherapy Program
The Children’s Hospital of Philadelphia
Assistant Professor of Pediatrics
Medical Director, Center for Cellular Immunotherapies
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Shannon L. Maude, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.
Grant/Research Support from Novartis Pharmaceuticals Corporation and Wugen.

Faculty/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through educational grants from Bristol Myers Squibb, Kite, A Gilead Company, Legend Biotech, and Novartis Pharmaceuticals Corporation.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice

Media: Enduring Material
Activity Release Date: June 5, 2022
Activity Expiration Date: July 4, 2023
Time to Complete Activity: 90 minutes

Activity Description

Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic.

Check out PeerView’s “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, advanced practice clinicians (including oncology NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with hematologic cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies
  • Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support
  • Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jason Westin, MD, MS, FACP
Associate Professor
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jason Westin, MD, MS, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ADC Therapeutics SA; AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; Merck & Co., Inc.; Monte Rosa Therapeutics, Inc.; MorphoSys AG; Novartis Pharmaceuticals Corporation; and Umoja Biopharma.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Kite/Gilead Sciences, Inc.; MorphoSys AG; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Shannon L. Maude, MD, PhD
Cancer Immunotherapy Program
The Children’s Hospital of Philadelphia
Assistant Professor of Pediatrics
Medical Director, Center for Cellular Immunotherapies
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Shannon L. Maude, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.
Grant/Research Support from Novartis Pharmaceuticals Corporation and Wugen.

Faculty/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through educational grants from Bristol Myers Squibb, Kite, A Gilead Company, Legend Biotech, and Novartis Pharmaceuticals Corporation.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 05, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Start

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Media: Enduring Material
Activity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes

Activity Description

Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
  • Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
  • Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Hussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France

Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.

Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida

Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

ACPE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Media: Enduring Material
Activity Release Date: June 4, 2022
Activity Expiration Date: July 3, 2023
Time to Complete Activity: 60 minutes

Activity Description

Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma
  • Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma
  • Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Hussein A. Tawbi, MD, PhD
Deputy Chair and Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein A. Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Eisai, Inc.; EMD Serono; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and RAPT Therapeutics.
Grant/Research Support from Boxer Capital, LLC.; Bristol Myers Squibb; Eisai, Inc.; Genentech, Inc.; Iovance Biotherapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Caroline Robert, MD, PhD
Head, Dermatology Unit
Director, Melanoma Research Team at INSERM U981
Gustave Roussy and Paris Saclay University
Villejuif, France

Caroline Robert, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd.; MSD; Novartis Pharmaceuticals Corporation; Pierre Fabre Group; Pfizer; and Sanofi.

Faculty/Planner
Ahmad A. Tarhini, MD, PhD
Senior Member, Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Chair, ORIEN Scientific Committee & ImmunoOncology Research Subcommittee
Tampa, Florida

Ahmad A. Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioNTech SE; Bristol Myers Squibb; Clinigen Limited; Eisai, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Instil Bio; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Partner Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Acrotech Biopharma; Agenus Inc.; Bristol Myers Squibb; Checkmate Pharmaceuticals; Clinigen Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Nektar Therapeutics; OncoSec Medical Incorporated; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-012-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

ACPE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 04, 2022
Credits: 1.0 CME / NCPD / CPE
PVI, PeerView Institute for Medical Education
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Start

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes

Activity Description

For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS.

At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination.

Target Audience

This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
  • Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
  • Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California

Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio, Inc.
Grant/Research Support from Genentech, Inc.

Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia

Heidi Crayton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Media: Enduring Material
Activity Release Date: June 3, 2022
Activity Expiration Date: July 2, 2023
Time to Complete Activity: 60 minutes

Activity Description

For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS.

At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination.

Target Audience

This activity has been designed to meet the educational needs of neurologists, internal and family medicine physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology
  • Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes
  • Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Bruce Cree, MD, PhD, MAS
George A. Zimmermann Endowed Professor in Multiple Sclerosis
Professor of Clinical Neurology
Clinical Research Director
UCSF Weill Institute for Neurosciences
Department of Neurology
University of California San Francisco
San Francisco, California

Bruce Cree, MD, PhD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Atara Biotherapeutics, Inc.; Autobahn Therapeutics; Avotres, Inc.; Biogen; EMD Serono, Inc.; Horizon Therapeutics plc; Neuron23; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; TG Therapeutics; and Therini Bio, Inc.
Grant/Research Support from Genentech, Inc.

Faculty/Planner
Heidi Crayton, MD
Medical Director
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia

Heidi Crayton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.
Grant/Research Support from Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with Atara Biotherapeutics, Inc.; Biogen; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; and TG Therapeutics, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-017-L01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 03, 2022
Credits: 1.0 CME / NCPD / CPE
PVI, PeerView Institute for Medical Education
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Start

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration.

At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
  • Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
  • Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
  • Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas

Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive role/ownership interest.

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi Genzyme.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Media: Enduring Material
Activity Release Date: June 2, 2022
Activity Expiration Date: July 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration.

At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS)
  • Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS
  • Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
  • Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Benjamin M. Greenberg, MD, MHS
Vice Chair of Clinical and Translational Research
Department of Neurology
University of Texas Southwestern Medical Center
Dallas, Texas

Benjamin M. Greenberg, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; EMD Serono, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Genzyme; Horizon Therapeutics plc; Immunovant, Inc.; IQVIA Inc.; Novartis Pharmaceuticals Corporation; Sandoz AG; and Signant Health.
Grant/Research Support from Anokion US Inc.; Clene Inc.; and Regeneron Pharmaceuticals Inc.
Other Financial or Material Support from GenrAB in an executive role/ownership interest.

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Novartis AG; and Sanofi Genzyme.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Sanofi Genzyme.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-018-L01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

June 02, 2022

Pages